darolutamide
bayer
['prostate', 'eortc,gucg 1532', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'bayer']
#ascogu: results from eortc-gucg 1532, a phase 2 randomized open-label study in men with hormone-naive #prostatecancer. #gu23: abstract 160, poster session a. 
Driving innovation in cancer care for patients.

By following this account you confirm that you are an HCP & accept our community guidelines: https://t.co/iYZUrNHHuk